New Drugs for Cancer



Thesis Statement:

PROGRAM IS TO MAKE PEOPLE AWARE ABOUT THE BUSINESS AND ECONOMIC ISSUES IN DEVELOPING DRUGS FOR CANCER PATIENTS.

Introduction

A various number new cancer related treatments have recently been entered in clinical practice (Checchi, 2003). Some are most expensive to purchase and utilized. Some of these medicines are offering very good benefits but some also providing not extraordinary results. Some medicines are very expensive but do not give long term healings to the patients (Hooijberg, 2006). Oncologists need to understand that how economic indicators are important to incorporate and specific evaluations of the medicines.

Discussion

If the cancer medicines are getting expensive with the same upward trend, researchers would need to address the economic factors of the intervention. It does not mean patients and doctors should use the least expensive medicines always (Checchi, 2003). It refers to the idea that doctors should consider the economic cost of the medicine as a one element in the decision making process (Hooijberg, 2006).

The economic impact of the cancer care is becoming the point attention for the biologist as they come to realize that high cost is attached with these medicines, which is not affordable by lots of people. However, cost has variations drastically (Checchi, 2003). For instance, 6 months of treatment includes thousands of dollars to spend on. Because of the high prices are involved in treatment process, that's why it is hard to figure out that what are the real effects. More expensive medicines are being introduced in the market but these medicines are far from the affordability of the users (Sparreboom, 2002). The most significant issue is to decide a balancing cost which should be related cost of treatment and the perceived benefits. Physicians should have conversation with the patients as well. Communicating with patients is very important.

Some studies have been done on this topic that whether it is good or bad to communicate with the patients regarding the cost of medicines. Practitioners are surveyed in this regard that whether it is helpful to communicate the cost structure of the medicines with users or not? Different views are collected on this topic. They have to look for the results that what are the results, expectations and price of the medicines (Hooijberg, 2006).

In the process of cost minimization, cost effectiveness, cost utility and cost benefit analysis the selection criteria is depending upon the availability of the data and ...